Trials / Active Not Recruiting
Active Not RecruitingNCT04393285
Abemaciclib and Letrozole to Treat Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Gynecologic Oncology Group · Network
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II single arm trial to determine the percentage of patients without evidence of disease progression on abemaciclib and letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abemaciclib | Abemaciclib 150mg orally twice a day |
| DRUG | Letrozole | Letrozole 2.5mg orally once a day |
Timeline
- Start date
- 2020-10-10
- Primary completion
- 2026-12-01
- Completion
- 2026-12-31
- First posted
- 2020-05-19
- Last updated
- 2026-03-09
Locations
29 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04393285. Inclusion in this directory is not an endorsement.